(Health Korea News / Changyong Lee) Research results have shown that human placenta extract may be effective in treating ‘atopic dermatitis’.
On the 26th, Professor Beomjun Kim’s research team from the Department of Dermatology at Chung-Ang University Hospital (Dr. Jeong-Ok Lee, Department of Dermatology, Chung-Ang University) announced on the 26th that they discovered the effectiveness of ‘Human Placenta Extract’ (HPE) in treating atopic dermatitis through experiments on human keratinocytes and atopic dermatitis mouse model. revealed.
‘HPE’ is a drug used as an injectable ingredient by separating and removing blood and hormones from the human placenta and breaking down the remaining protein into amino acids. It is also called ‘Human Placenta Hydrolysate (HPH).’ ‘HPE’ or ‘HPH’ contains various bioactive substances that reduce inflammation, improve fatigue, and help wound healing. This is the first time that research has shown that it is effective in treating ‘atopic dermatitis’.
In this study, the research team applied a mixture of 2,4-dinitrochlorobenzene (DNCD), an atopic dermatitis-causing substance, to the back of experimental mice using human keratinocytes (HaCaT) and an atopic dermatitis mouse model to induce atopic dermatitis. Afterwards, ‘Human Placenta Extract (HPH)’ and ‘Dexamethasone (DEX)’, which was previously used as a skin inflammation treatment, were injected subcutaneously and intraperitoneally, respectively, and their efficacy in treating atopic dermatitis was evaluated.
As a result, the research team confirmed that injection of ‘human placental extract (HPH)’ significantly reduced the production of reactive oxygen species (ROS) in human keratinocytes (HaCaT), thereby suppressing oxidative stress.
In addition, the atopic dermatitis mouse model injected with ‘human placenta extract (HPH)’ showed that the concentration of IL-4 and IgE, the main cytokines of atopic skin inflammation, decreased by 60% and 27%, respectively, in the blood.
The research team said, “We were able to confirm that atopic skin lesions were improved by reducing macrophage infiltration and epidermal thickness,” and added, “Human placenta extract (HPH) injection effectively suppresses the progression of atopic dermatitis and is a useful treatment for atopic dermatitis-like skin diseases.” “We confirmed the possibility of it being used,” he explained.
However, given that this study was an animal experiment, clinical trials are likely to be inevitable for future commercialization.
Professor Kim Beom-jun said, “After laboratory research and animal testing, we hope to conduct future research to see if it can actually be applied to atopic dermatitis patients through full-scale clinical research.” He added, “It is difficult to use expensive biological agents or there are cases where treatment is not possible. “If possible, I believe HPH injection could be used as an option for atopic dermatitis treatment,” he said.
This research paper was published in the August issue of the Journal of Microbiology and Biotechnology, and was selected as an excellent paper by the Korean Society of Microbiology and Biotechnology (KMB), the research team announced. The title of the paper is ‘Human Placenta Extract(HPH) Suppresses Inflammatory Responses in TNF-α/IFN-γ-Stimulated HaCaT Cells and a DNCB Atopic Dermatitis(AD)-Like Mouse Model. ‘Inhibition of inflammatory response in IFN-γ stimulated HaCaT cells and DNCB atopic dermatitis (AD)-like mouse model’.
For reference, this animal test was conducted at the request of Green Cross (Wellbeing), which produces and sells human placenta injections. Therefore, Professor Beomjun Kim’s research team is expected to lead Green Cross Wellbeing’s clinical research in the future.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
